Lixte Biotechnology Holdings Inc (LIXTW) News

Form 8-K - Current report

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition...

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition...

Form 8-K - Current report

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process...

Form 8-K - Current report

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10...

Mixed Shelf Filing Gives Micro Cap Delayed Boost

A California-based biotech company is finding pretty serious success on Wednesday a day after the company filed a registration statement covering...

Biotech Steals The Show Following Pre-Clinical Data Announcement

A California-based biotech company stirred things up on Wednesday after it was announced the publication of preclinical data on its lead clinical...

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN...